Tests tralokinumab with steroid creams for eczema in children and infants
Tests tralokinumab injections with steroid creams in children and infants with moderate-to-severe eczema.
Plain-language title generated from the registry record
Registry title: A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Key facts
- Where
- Buxtehude, Dresden, Mainz, Osnabrueck, Potsdam, Tuebingen, and Wuppertal, GermanySee the 7 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for infants and children with moderate-to-severe atopic dermatitis who did not respond well to mid-strength topical steroids.
- Age
- 6 months to under 12 years, with a body weight of at least 9 kg (20 lb).
- Sex
- All sexes can join.
- Disease stage
- Moderate-to-severe atopic dermatitis, diagnosed by the Hanifin and Rajka (1980) criteria. Skin involvement of at least 10% of body surface area, EASI score of at least 16, IGA score of at least 3. Atopic dermatitis for at least 12 months (age 6 years and older) or at least 3 months (age 6 months to under 6 years).
- Earlier treatment
- A documented poor response to mid-strength topical corticosteroids (TCS) within the 6 months before screening.
Main reasons for not taking part
- Topical treatments (TCS, TCI, PDE-4, JAK) or bleach baths within 1 week before baseline
- Systemic immunosuppressive drugs or systemic corticosteroids within 4 weeks before baseline
- Tanning beds or phototherapy within 4 weeks before baseline
- Any vaccine within 30 days before baseline
- Past or current hepatitis B or C
Read by machine on 12 November 2026.
Where in Germany
- Elbe Kliniken Stade-Buxtehude Elbe Klinikum Buxtehude gGmbHBuxtehude, GermanyNo longer taking part
- Technische Universitaet DresdenDresden, GermanyNo longer taking part
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyNo longer taking part
- Klinische Forschung OsnabrueckOsnabrueck, GermanyNo longer taking part
- MVZ Corius Potsdam GmbHPotsdam, GermanyNo longer taking part
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyNo longer taking part
- Helios Universitaetsklinikum WuppertalWuppertal, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- LEO Pharma
- Trial code
- NCT06311682EU 2023-503630-44-00
- Record updated
- 9 November 2026
- Original description
The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits every 2 weeks for the first year and every 6 weeks thereafter. Some of the visits will be conducted by phone.Read full original descriptionShow less
A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis. The Trial is Randomized, Double-blind, Placebo-controlled, and Parallel-group for Children (Age 2 to <12 Years) and Open-label and Single-group for Infants (Age 6 Months to <2 Years)
The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits every 2 weeks for the first year and every 6 weeks thereafter. Some of the visits will be conducted by phone.
The study involves two different age groups: children aged 2 to under 12 years and infants aged 6 months to under 2 years. This trial compares tralokinumab +TCS to placebo + TCS for children with moderate-to-severe AD and evaluates tralokinumab + TCS for infants with moderate-to-severe AD. Infants will not receive placebo. All subjects will go through a screening process, which is the first part of the trial and will last up to 4 weeks. During this period, it will be checked if the child or infant meets the criteria to participate in the trial.
The children will be randomly assigned to receive tralokinumab + TCS or placebo + TCS for the initial 16 weeks, with the treatment being double-blinded. During the first 16 weeks, children will have a 2 out of 3 chance of getting tralokinumab and a 1 out of 3 chance of getting placebo. Thereafter, all subjects will receive tralokinumab + TCS. The infants will receive tralokinumab + TCS as open-label treatment for the entire treatment period, meaning that the participants will know they are receiving tralokinumab. After stopping treatment, all participants will enter a 4-week safety follow-up period.
Inclusion: Age 6 months to <12 years at screening; Body weight ≥9 kg at screening; Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD; History of AD for: ≥12 months for subjects aged ≥6 years at screening and ≥3 months for subjects aged 6 months to <6 years at screening; Documented inadequate response to mid-strength TCS within 6 months before the screening visit; AD involvement of ≥10% body surface area at screening and baseline according to component A of SCORAD; An EASI score of ≥16 at screening and baseline; An IGA score of ≥3 at screening and baseline; A Child Worst Itch NRS average score of ≥4 (subjects aged ≥6 years at screening) or a Scratch ObsRO average score of ≥4 (subjects aged <6 years at screening) during the week prior to baseline.
Exclusion: Treatment with the topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), topical phosphodiesterase-4 inhibitors (PDE-4), and topical Janus kinase inhibitors (JAK) within 1 week prior to baseline; Treatment with bleach baths within 1 week prior to baseline; Treatment with the immunomodulatory medications systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, Janus kinase inhibitors) and systemic corticosteroids (excludes inhaled, ophthalmic, or intranasal delivery) within 4 weeks prior to baseline; Use of tanning beds or phototherapy within 4 weeks prior to baseline; Treatment with a live (attenuated) or non-live vaccine within 30 days prior to the baseline visit; Clinically significant active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals or antiprotozoal within 2 weeks before the baseline visit; Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment such as seborrheic dermatitis, active skin infection, scabies, cutaneous T cell lymphoma, or psoriasis; History of past or current hepatitis B or C including a positive hepatitis B or C test at screening.